Nicked β2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis

Blood

Volumn 103, Issue 10, 2004, Pages 3766-3772

  Yasuda, Shinsuke ^b   Atsumi, Tatsuya ^a   Ieko, Masahiro ^b   Matsuura, Eiji ^b   Kobayashi, Kazuko ^b   Inagaki, Junko ^b   Kato, Hisao ^b   Tanaka, Hideyuki ^b   Yamakado, Minoru ^b   Akino, Minoru ^b   Saitou, Hisatoshi ^b   Amasaki, Yoshiharu ^b   Jodo, Satoshi ^b   Amengual, Olga ^b   Koike, Takao ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; FIBRIN; PHOSPHOLIPID; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER; GLYCOPROTEIN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; KRINGLE DOMAIN; MAJOR CLINICAL STUDY; MALE; NEGATIVE FEEDBACK; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; THROMBOSIS; BLOOD; CASE CONTROL STUDY; DRUG ANTAGONISM; FEEDBACK SYSTEM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTEIN BINDING;

AGED; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBRAL INFARCTION; FEEDBACK, BIOCHEMICAL; FEMALE; FIBRINOLYSIS; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PLASMIN; PLASMINOGEN; PROTEIN BINDING; THROMBOSIS;

EID: 2342472560     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2712     Document Type: Article

References (38)

1. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
3. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336:177-178.
4. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341-344.
5. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA. 1993;90:2141-2145.
6. Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood. 1998;91:4173-4179.
7. Nimpf J, Bevers EM, Bomans PHH, et al. Prothrombinase activity of human platelets inhibited by β2-glycoprotein I. Biochem Boiphys Acta. 1986;884:142-149.
8. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost. 1993;70:342-345.
9. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost. 1995; 73:798-804.
10. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996;75: 49-55.
11. Ieko M, Ichikawa K, Triplett DA, et al. β2-Glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum. 1999;42:167-174.
12. Nakaya Y, Schaefer EJ, Brewer HBJ. Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I). Biochem Biophys Res Commun. 1980;95:1168-1172.
13. Wurm H, Beubler E, Polz E, Holasek A, Kostner G. Studies on the possible function of β2-glycoprotein-I: influence in the triglyceride metabolism in the rat. Metabolism. 1982;31:484-486.
14. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569-573.
15. Chonn A, Semple SC, Cullis PR. β2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem. 1995;270:25845-25849.
16. Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus; I: opsonization by antiphospholipid antibodies. Arthritis Rheum. 1998;41:205-214.
17. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus; II: role of β2-glycoprotein I. Arthritis Rheum. 1998;41:215-223.
18. Wallen P, Wiman B. Chanacterization of human plasminogen; I: on the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochim Biophys Acta. 1970;221:20-30.
19. Ponting CP, Holland SK, Cederholm-Williams SA, et al. The compact domain conformation of human Glu-plasminogen in solution. Biochim Biophys Acta. 1992;1159:155-161.
20. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest. 1979;63:877-884.
21. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
22. Horbach DA, van Oort ET, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-Glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999;81:87-95.
23. Itoh Y, Inuzuka K, Kohno I, et al. Highly increased plasma concentrations of the nicked form of β2-glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem (Tokyo). 2000;128:1017-1024.
24. Igarashi M, Matsuura E, Igarashi Y, et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood. 1996;87:3262-3270.
25. Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of andcardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;146: 3885-3891.
26. Matsuura E, Inagaki J, Kasahara H, et al. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol. 2000;12:1183-1192.
27. Ranby M, Wallen P. A sensitive parabolic rate assay for tissue plasminogen activator. In: Davidson JF, Nilson IM, Asted B, eds. Progress in Fibrinolysis. Vol 5. New York, NY: Churchill Livingstone; 1981:232-235.
28. Bouma B, de Groot PG, van den Eisen JM, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18:5166-5174.
29. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18: 6228-6239.
30. Hoshino M, Hagihara Y, Nishli I, Yamazaki T, Kato H, Goto Y. Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance. J Mol Biol. 2000;304:927-939.
31. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983;258:4249-4256.
32. Wu HL, Chang BI, Wu DH, et al. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem. 1990;265:19658-19664.
33. Christensen U. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen. FEBS Lett. 1985;182:43-46.
34. Tran-Thang C, Kruithof EK, Atkinson J, Bachmann F. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem. 1986;160: 599-604.
35. Matsuka YV, Novokhatny VV, Kudinov SA. Fluorescence spectroscopic analysis of ligand binding to kringle 1 + 2 + 3 and kringle 1 fragments from human plasminogen. Eur J Biochem. 1990;190: 93-97.
36. Chang Y, Mochalkln I, McCance SG, Cheng B, Tulinsky A, Castellino FJ. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry. 1998;37:3258-3271.
37. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78: 3114-3124.
38. Thorsen S, Clemmensen I, Sottrup-Jensen L, Magnusson S. Adsorption to fibrin of native fragments of known primary structure from human plasminogen. Biochem Blophys Acta. 1981;668: 377-387.